Vasodilatory properties of recombinant maxadilan

Area of Science:

• Pharmacology
• Vascular Biology
• Biochemistry

Background:

• Maxadilan is a peptide identified in the salivary glands of the sand fly Lutzomyia longipalpis, a known vector for leishmaniasis.
• This peptide is recognized as the most potent known vasodilator, inducing erythema even at femtomolar concentrations.

Purpose of the Study:

• To investigate the vasodilatory potency and underlying mechanism of maxadilan in isolated arterial smooth muscle.
• To compare the efficacy of maxadilan with nitroglycerin in various arterial beds.

Main Methods:

• Dose-dependent arterial relaxation assays were performed on isolated rabbit thoracic aorta, abdominal aorta, carotid artery, and iliac artery.
• The role of endothelium, specific inhibitors (K(+)-channel antagonists, methylene blue, quinacrine, ouabain), and signaling pathways (cAMP) were assessed.
• Intracellular calcium levels and cAMP content in rabbit aortic smooth muscle cells were measured.

Main Results:

• Maxadilan demonstrated potent, dose-dependent arterial relaxation across all tested arteries with EC50 values in the low nanomolar range.
• Maxadilan was significantly more potent (at least sevenfold) than nitroglycerin in all arterial preparations.
• The vasodilatory effect was endothelium-independent and mediated by an increase in cyclic adenosine monophosphate (cAMP) and a reduction in intracellular calcium.

Conclusions:

• Maxadilan is a highly potent vasodilator peptide derived from sand fly saliva.
• Its mechanism involves a cAMP-dependent pathway leading to reduced intracellular calcium levels in vascular smooth muscle.
• Maxadilan represents a promising subject for further research in vascular pharmacology.